长春瑞宾联合顺铂二线治疗复发转移性乳腺癌

The Clinical Study of Navelbine-Cisplatin Combination as Second-Line in Treament of Metastatic Breast Cancer

目的 探索长春瑞宾联合顺铂二线化疗方案对复发转移性乳腺癌的疗效和安全性。方法 采用NP方案即长春瑞宾(NVB)2 5mg/m2 ,iv ,d1,8;顺铂(DDP) 80mg/m2 ,iv ,d1;作为二线方案治疗经病理和(或)细胞学诊断的3 5例晚期乳腺癌,2 2例曾用含阿霉素方案化疗,经治疗后复发或进展。结果 可评价疗效的3 5例中,无CR(完全缓解)、PR(部分缓解) 2 2例,SD(稳定) 8例,PD(进展) 5例,有效率62 .8% ;中位生存期18个月;1年生存率68.6%。化疗的不良反应主要是血液学毒性,但患者可以耐受。结论 NVB联合DDP用于二线化疗方案治疗复发转移性乳腺癌临床有效,患者耐受性尚可。

Objective To evaluate the efficacy and toxicity of the second-line treatment in patients with metastatic breast cancer.Methods 35 patients with histologically and/or cytologically confirmed advanced breast cancer were treated with Navel (NVB) 25mg/m 2 on day 1, days 8 and Cisplatin (DDP) 80mg/m 2 on day 1 every 3 weeks. 22 patients had received prior anthracycline-containing chemotherapy. All patients had relapsed after receiving chemotherapy regimen. Result 22 of 35 assessable patients achieved partial response (PR), 8 had stable disease (SD), 5 had progressive disease (PD), there was no complete response (CR). The response rate was 62.8% and the median survival of all patients was 18 months. One-year survival rate was 68.6%. Hematologic toxicity was the main side effect in this trial, and they were well tolerated. Conclusion NVB combined with DDP was an effective regimen with tolerable toxicity in the second-line treatment of metastatic breast cancer.